JP2011514150A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011514150A5 JP2011514150A5 JP2010546038A JP2010546038A JP2011514150A5 JP 2011514150 A5 JP2011514150 A5 JP 2011514150A5 JP 2010546038 A JP2010546038 A JP 2010546038A JP 2010546038 A JP2010546038 A JP 2010546038A JP 2011514150 A5 JP2011514150 A5 JP 2011514150A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- light chain
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004965 antibodies Human genes 0.000 claims 20
- 108090001123 antibodies Proteins 0.000 claims 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 238000006467 substitution reaction Methods 0.000 claims 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229920000023 polynucleotide Polymers 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N (+)-methoprene Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 102100016263 IFNAR1 Human genes 0.000 claims 1
- 101710030378 IFNAR1 Proteins 0.000 claims 1
- 206010027665 Immune disorder Diseases 0.000 claims 1
- 206010021425 Immune system disease Diseases 0.000 claims 1
- 230000027455 binding Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Claims (21)
- IFNAR1に特異的な改変IgGクラスモノクローナル抗体であって、Fc領域に、Kabatに説明されるEUインデックスにより番号付けしたL234F、L235E、およびP331Sからなる群より選択される少なくとも1つのアミノ酸置換を含み、未改変抗体と比較して少なくとも1つのFcリガンドに対して低下した親和性を示す、上記抗体。
- P331Sのアミノ酸置換を含む、請求項１に記載の抗体。
- アミノ酸置換:L234FおよびL235Eを含む、請求項１に記載の抗体。
- アミノ酸置換:L234F、L235EおよびP331Sを含む、請求項１に記載の抗体。
- Fc領域のL235Eのアミノ酸置換を含む、請求項１に記載の抗体。
- Fc領域にアミノ酸置換S228Pをさらに含む、請求項１に記載の抗体。
- 表2から選択される少なくとも1つの相補性決定領域(CDR)を含む、請求項１〜６のいずれか１項に記載の抗体。
- 以下のCDR:
a. 配列番号３１を含むヒト軽鎖可変領域CDR1;
b. 配列番号３２を含むヒト軽鎖可変領域CDR2;
c. 配列番号３３を含むヒト軽鎖可変領域CDR3;
d. 配列番号３４を含むヒト軽鎖可変領域CDR1;
e. 配列番号３５を含むヒト軽鎖可変領域CDR2;および
f. 配列番号３６を含むヒト軽鎖可変領域CDR3
を含む、請求項１〜７のいずれか１項に記載の抗体。 - 以下のCDR:
a. 配列番号２１を含むヒト軽鎖可変領域CDR1;
b. 配列番号２２を含むヒト軽鎖可変領域CDR2;
c. 配列番号２３を含むヒト軽鎖可変領域CDR3;
d. 配列番号２４を含むヒト軽鎖可変領域CDR1;
e. 配列番号２５を含むヒト軽鎖可変領域CDR2;および
f. 配列番号２６を含むヒト軽鎖可変領域CDR3
を含む、請求項１〜７のいずれか１項に記載の抗体。 - 以下の可変領域:
a. 配列番号３８のアミノ酸配列を含むヒト重鎖可変領域;および
b. 配列番号４０のアミノ酸配列を含むヒト軽鎖可変領域
を含む、請求項１〜７のいずれか１項に記載の抗体。 - 以下の可変領域:
a. 配列番号２８のアミノ酸配列を含むヒト重鎖可変領域;および
b. 配列番号３０のアミノ酸配列を含むヒト軽鎖可変領域
を含む、請求項１〜７のいずれか１項に記載の抗体。 - 配列番号４１の軽鎖定常領域配列を含む、請求項１〜７のいずれか１項に記載の抗体。
- 配列番号４２の重鎖定常領域を含む、請求項１〜７のいずれか１項に記載の抗体。
- 配列番号４１のアミノ酸配列を有する軽鎖定常領域および配列番号４２のアミノ酸配列を有する重鎖定常領域を含む、請求項１〜７のいずれか１項に記載の抗体。
- EUインデックスナンバリングシステムにより定義される214、221、356および358からなる群より選択される少なくとも1以上の位置の対立遺伝子変異を含む重鎖アミノ酸配列を含む、請求項１２〜１４のいずれか１項に記載の抗体。
- 請求項１〜１５のいずれか１項に記載の抗体をコードするポリヌクレオチド配列を含む、単離核酸。
- ベクターを含むかまたは該ベクターを用いて形質転換されている宿主細胞であって、該ベクターはプロモーターに機能的に連結された請求項１６に記載のポリヌクレオチドを含む、前記宿主細胞。
- 請求項１〜１５のいずれか１項に記載の抗体、および製薬上許容される賦形剤を含む、医薬組成物。
- 免疫障害を伴う状態または疾患の治療のための医薬の製造における、請求項１〜１５のいずれか１項に記載の抗体または請求項１８に記載の組成物の使用。
- 前記疾患または障害が全身性エリテマトーデスである、請求項１９に記載の使用。
- 請求項１〜１５のいずれか１項に記載の抗体の製造方法。
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US696208P | 2008-02-08 | 2008-02-08 | |
| US61/006,962 | 2008-02-08 | ||
| US3461808P | 2008-03-07 | 2008-03-07 | |
| US61/034,618 | 2008-03-07 | ||
| US4997008P | 2008-05-02 | 2008-05-02 | |
| US61/049,970 | 2008-05-02 | ||
| PCT/US2009/033358 WO2009100309A2 (en) | 2008-02-08 | 2009-02-06 | Anti-ifnar1 antibodies with reduced fc ligand affinity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011514150A JP2011514150A (ja) | 2011-05-06 |
| JP2011514150A5 true JP2011514150A5 (ja) | 2012-03-15 |
| JP5608100B2 JP5608100B2 (ja) | 2014-10-15 |
Family
ID=40952709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010546038A Active JP5608100B2 (ja) | 2008-02-08 | 2009-02-06 | 低下したＦｃリガンド親和性を有する抗ＩＦＮＡＲ１抗体 |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US20110059078A1 (ja) |
| EP (1) | EP2250279B1 (ja) |
| JP (1) | JP5608100B2 (ja) |
| KR (2) | KR101666229B1 (ja) |
| CN (1) | CN101952454B (ja) |
| AU (1) | AU2009212273B2 (ja) |
| BR (2) | BR122020023189B1 (ja) |
| CA (1) | CA2713981C (ja) |
| CY (1) | CY1117827T1 (ja) |
| DK (1) | DK2250279T3 (ja) |
| ES (1) | ES2581917T3 (ja) |
| FI (1) | FIC20220024I1 (ja) |
| FR (1) | FR22C1019I2 (ja) |
| HK (1) | HK1149297A1 (ja) |
| HR (1) | HRP20160855T1 (ja) |
| HU (3) | HUE028958T2 (ja) |
| LT (1) | LTPA2022514I1 (ja) |
| MX (1) | MX2010008578A (ja) |
| NL (1) | NL301175I2 (ja) |
| NO (1) | NO2022016I1 (ja) |
| PL (1) | PL2250279T3 (ja) |
| PT (1) | PT2250279E (ja) |
| SG (1) | SG188129A1 (ja) |
| SI (1) | SI2250279T1 (ja) |
| WO (1) | WO2009100309A2 (ja) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2603408C (en) | 2005-03-31 | 2018-08-21 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| CN105177091A (zh) | 2006-03-31 | 2015-12-23 | 中外制药株式会社 | 用于纯化双特异性抗体的抗体修饰方法 |
| ES2892925T3 (es) | 2006-03-31 | 2022-02-07 | Chugai Pharmaceutical Co Ltd | Métodos para controlar la farmacocinética en sangre de anticuerpos |
| US9096651B2 (en) | 2007-09-26 | 2015-08-04 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
| CA2978687C (en) | 2007-09-26 | 2020-02-18 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
| ES2585480T3 (es) | 2007-12-05 | 2016-10-06 | Chugai Seiyaku Kabushiki Kaisha | Anticuerpo anti-NR10 y uso del mismo |
| KR101666229B1 (ko) * | 2008-02-08 | 2016-10-14 | 메디뮨 엘엘씨 | Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체 |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| US9228017B2 (en) | 2009-03-19 | 2016-01-05 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| EP2409990A4 (en) | 2009-03-19 | 2013-01-23 | Chugai Pharmaceutical Co Ltd | VARIANT OF A CONSTANT ANTIBODY REGION |
| KR20120024763A (ko) | 2009-05-15 | 2012-03-14 | 추가이 세이야쿠 가부시키가이샤 | 항ａｘｌ 항체 |
| US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
| PL2506871T3 (pl) | 2009-11-30 | 2017-03-31 | Janssen Biotech, Inc | Przeciwciała ze zmutowanymi regionami Fc i utraconymi funkcjami efektorowymi |
| US10053513B2 (en) | 2009-11-30 | 2018-08-21 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
| EP2543730B1 (en) | 2010-03-04 | 2018-10-31 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| CA2824279A1 (en) * | 2010-12-22 | 2012-06-28 | Cephalon Australia Pty Ltd | Modified antibody with improved half-life |
| CA2828289C (en) | 2011-03-29 | 2020-07-21 | Roche Glycart Ag | Antibody fc variants |
| EP2725101B1 (en) * | 2011-06-21 | 2017-09-27 | Kyowa Hakko Kirin Co., Ltd. | Protein comprising truncated form of extracellular domain protein of frizzled 2, and pharmaceutical composition for treating bone diseases which comprises said protein |
| MX2014005196A (es) * | 2011-11-01 | 2014-05-28 | Roche Glycart Ag | Modelo de citotoxidad celular dependiente de anticuerpos (adcc) in vivo. |
| CA2876636C (en) * | 2012-06-13 | 2022-09-13 | Medimmune, Llc | Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies |
| JP2015531748A (ja) | 2012-06-21 | 2015-11-05 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | 改変ｆｃエフェクター機能を有するインクレチン受容体リガンドポリペプチドｆｃ領域融合ポリペプチド及び複合物 |
| EP2869845B1 (en) | 2012-07-06 | 2019-08-28 | Genmab B.V. | Dimeric protein with triple mutations |
| RS57704B1 (sr) | 2012-07-13 | 2018-12-31 | Roche Glycart Ag | Bispecifična anti-vegf/anti-ang-2 antitela i njihova primena u lečenju vaskularnih bolesti oka |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| JP6623353B2 (ja) | 2013-09-13 | 2019-12-25 | ベイジーン スウィッツァーランド ゲーエムベーハー | 抗ｐｄ−１抗体並びにその治療及び診断のための使用 |
| JP6534615B2 (ja) | 2013-09-27 | 2019-06-26 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| CN107074957B (zh) * | 2014-01-13 | 2021-05-07 | 希望之城公司 | 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法 |
| CN106132994A (zh) * | 2014-03-05 | 2016-11-16 | Ucb生物制药私人有限公司 | 多聚体Fc蛋白 |
| LT3151921T (lt) | 2014-06-06 | 2019-12-10 | Bristol Myers Squibb Co | Antikūnai prieš gliukokortikoidu indukuojamą naviko nekrozės faktoriaus receptorių (gitr) ir jų panaudojimas |
| TWI726608B (zh) | 2014-07-03 | 2021-05-01 | 英屬開曼群島商百濟神州有限公司 | 抗pd-l1抗體及其作為治療及診斷之用途 |
| TW201619200A (zh) | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗－ｏｘ４０抗體及其用途 |
| JP6805142B2 (ja) | 2014-11-21 | 2020-12-23 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃｄ７３に対する抗体およびその使用 |
| WO2016081746A2 (en) | 2014-11-21 | 2016-05-26 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
| WO2016131893A1 (en) | 2015-02-18 | 2016-08-25 | Medimmune Limited | Incretin fusion polypeptides |
| PL3263132T3 (pl) | 2015-02-27 | 2024-04-15 | Chugai Seiyaku Kabushiki Kaisha | Kompozycja do leczenia chorób związanych z il-6 |
| WO2016159213A1 (ja) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| JP6812364B2 (ja) | 2015-06-03 | 2021-01-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 癌診断用抗ｇｉｔｒ抗体 |
| EP3769781B1 (en) * | 2015-08-19 | 2023-04-19 | Astrazeneca AB | Stable anti-ifnar1 formulation |
| PE20181300A1 (es) | 2015-11-02 | 2018-08-09 | Five Prime Therapeutics Inc | Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer |
| SG11201803817PA (en) | 2015-11-19 | 2018-06-28 | Bristol Myers Squibb Co | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
| EP3398965A4 (en) | 2015-12-28 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR PROMOTING THE EFFICACY OF PURIFYING A POLYPEPTIDE CONTAINING AN FC REGION |
| US20190071514A1 (en) * | 2016-03-14 | 2019-03-07 | Innate Pharma | Anti-cd39 antibodies |
| CN106243226B (zh) * | 2016-08-05 | 2019-02-12 | 北京智仁美博生物科技有限公司 | 抗人ifnar1的抗体及其用途 |
| CN110087680B (zh) | 2016-08-19 | 2024-03-19 | 百济神州有限公司 | 使用包含btk抑制剂的组合产品治疗癌症 |
| SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
| KR20240076829A (ko) | 2016-11-16 | 2024-05-30 | 아블린쓰 엔.브이. | Cd123 및 tcr 알파/베타에 결합할 수 있는 t 세포 동원 폴리펩티드 |
| US20200031943A1 (en) * | 2017-03-21 | 2020-01-30 | Austrianni Gmbh | Type 1 interferon receptor antagonists for use in methods of treating tuberculosis and other infectious diseases |
| WO2018201014A1 (en) | 2017-04-28 | 2018-11-01 | Five Prime Therapeutics, Inc. | Methods of treatment with cd80 extracellular domain polypeptides |
| EP3620531A4 (en) | 2017-05-02 | 2021-03-17 | National Center of Neurology and Psychiatry | METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS |
| KR20200006115A (ko) | 2017-05-16 | 2020-01-17 | 브리스톨-마이어스 스큅 컴퍼니 | 항-gitr 효능제 항체에 의한 암의 치료 |
| AU2018290532A1 (en) | 2017-06-26 | 2019-11-21 | Beigene, Ltd. | Immunotherapy for hepatocellular carcinoma |
| EP3675906A4 (en) | 2017-08-28 | 2021-05-26 | Angiex, Inc. | ANTI-TM4SF1 ANTIBODIES AND METHOD OF USING THEREOF |
| EP3694885A1 (en) | 2017-10-14 | 2020-08-19 | CytomX Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
| WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
| WO2019160976A1 (en) | 2018-02-14 | 2019-08-22 | Viela Bio, Inc. | Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases |
| CN116327926A (zh) | 2018-03-15 | 2023-06-27 | 中外制药株式会社 | 对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法 |
| KR102629294B1 (ko) * | 2018-09-18 | 2024-01-30 | 아이-맵 바이오파마 (항저우) 컴퍼니 리미티드 | 자가면역 질환을 치료하기 위한 항-ifnar1 항체 |
| CN113508138B (zh) | 2019-02-15 | 2024-08-09 | 阿斯利康(瑞典)有限公司 | I型干扰素介导的障碍 |
| WO2020172625A1 (en) | 2019-02-21 | 2020-08-27 | Lilly Kathline | Workout station |
| CN110914296B (zh) | 2019-02-22 | 2021-02-19 | 武汉友芝友生物制药有限公司 | 改造的Fc片段，包含其的抗体及其应用 |
| EP4017542A1 (en) | 2019-10-04 | 2022-06-29 | Tae Life Sciences | Antibody compositions comprising fc mutations and site-specific conjugation properties |
| AU2020382850A1 (en) | 2019-11-11 | 2022-06-23 | Astrazeneca Ab | Type I interferon inhibition in systemic lupus erythematosus |
| GB2595299B (en) | 2020-05-21 | 2022-08-03 | Mabsolve Ltd | Modified immunoglobulin FC regions |
| AU2021279277A1 (en) | 2020-05-29 | 2023-02-02 | Astrazeneca Ab | Treatment of cardiometabolic disease with inhibitors of type I interferon signalling |
| TW202237647A (zh) | 2020-10-08 | 2022-10-01 | 瑞典商阿斯特捷利康公司 | 狼瘡發作之治療 |
| WO2022097065A2 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | ANTIBODY Fc VARIANTS |
| CN116997359A (zh) | 2020-11-18 | 2023-11-03 | 阿斯利康(瑞典)有限公司 | 类固醇节制 |
| KR20240000557A (ko) | 2021-04-23 | 2024-01-02 | 아스트라제네카 아베 | 피부 홍반 루푸스의 치료 |
| KR20240001704A (ko) | 2021-04-23 | 2024-01-03 | 아스트라제네카 아베 | 항-i형 inf 수용체 항체 아니프롤루맙을 이용한 루푸스 신염의 치료 |
| WO2022223714A1 (en) | 2021-04-23 | 2022-10-27 | Astrazeneca Ab | Anti-ifnar1 dosing regime for subcutaneous injection |
| BR112023023391A2 (pt) | 2021-05-12 | 2024-01-23 | Astrazeneca Ab | Inibidor de diminuição de esteroide de receptor de interferon tipo 1 em pacientes com lúpus eritematoso sistêmico |
| CN113278071B (zh) | 2021-05-27 | 2021-12-21 | 江苏荃信生物医药股份有限公司 | 抗人干扰素α受体1单克隆抗体及其应用 |
| EP4377349A1 (en) | 2021-07-27 | 2024-06-05 | Astrazeneca AB | Treatment of lupus |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| IL311691A (en) | 2021-10-04 | 2024-05-01 | Astrazeneca Ab | Lupus treatment |
| EP4423123A1 (en) | 2021-10-28 | 2024-09-04 | Novartis AG | Engineered fc variants |
| TW202400658A (zh) | 2022-04-26 | 2024-01-01 | 瑞士商諾華公司 | 靶向ｉｌ—１３和ｉｌ—１８的多特異性抗體 |
| WO2023239803A1 (en) | 2022-06-08 | 2023-12-14 | Angiex, Inc. | Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same |
| EP4299731A1 (en) | 2022-06-29 | 2024-01-03 | ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN NANOCIENCIAS "CIC nanoGUNE" | Synthetic primase-polymerase and uses thereof |
| WO2024027793A1 (en) * | 2022-08-05 | 2024-02-08 | I-Mab Biopharma (Hangzhou) Co., Ltd. | Bispecific antibodies targeting ifnar1 and blys |
| WO2024079241A1 (en) | 2022-10-13 | 2024-04-18 | Astrazeneca Ab | Treatment of lupus |
| WO2024165671A1 (en) | 2023-02-08 | 2024-08-15 | Immunos Therapeutics Ag | FUSION PROTEINS OF ß2 MICROGLOBULIN, HLA HEAVY CHAIN POLYPEPTIDES, AND INHIBITOR OF CD47-SIRPA |
Family Cites Families (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| CA1340288C (en) | 1988-09-02 | 1998-12-29 | Robert Charles Ladner | Generation and selection of novel binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE68925966T2 (de) | 1988-12-22 | 1996-08-29 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| ATE356869T1 (de) | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| ATE269401T1 (de) | 1991-04-10 | 2004-07-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
| AU2238292A (en) | 1991-06-14 | 1993-01-12 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| DE69233745D1 (de) | 1991-12-02 | 2008-10-23 | Cambridge Antibody Tech | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
| CA2507749C (en) | 1991-12-13 | 2010-08-24 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| EP0563487A1 (en) | 1992-03-31 | 1993-10-06 | Laboratoire Europeen De Biotechnologie S.A. | Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| EP0640094A1 (en) | 1992-04-24 | 1995-03-01 | The Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| CA2141602A1 (en) | 1992-08-26 | 1994-03-03 | Philip Leder | Use of the cytokine ip-10 as an anti-tumor agent |
| US5540926A (en) * | 1992-09-04 | 1996-07-30 | Bristol-Myers Squibb Company | Soluble and its use in B cell stimulation |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| AU5670194A (en) | 1992-11-20 | 1994-06-22 | Enzon, Inc. | Linker for linked fusion polypeptides |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| US6299870B1 (en) | 1993-06-11 | 2001-10-09 | Pbl Biomedical Laboratories | Mutant human interferons |
| CA2164811A1 (en) | 1993-06-11 | 1994-12-22 | Sidney Pestka | Super proteins including interferons and interleukins |
| EP0714409A1 (en) * | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
| EP0730740B1 (en) | 1993-11-23 | 1998-02-11 | Genentech, Inc. | Kinase receptor activation assay |
| AU696293B2 (en) | 1993-12-08 | 1998-09-03 | Genzyme Corporation | Process for generating specific antibodies |
| EP0744958B1 (en) | 1994-01-31 | 2003-06-25 | Trustees Of Boston University | Polyclonal antibody libraries |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| EP1709970A1 (en) | 1995-04-27 | 2006-10-11 | Abgenix, Inc. | Human antibodies against EGFR, derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP2305027B1 (en) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US7227002B1 (en) | 1997-04-14 | 2007-06-05 | Micromet Ag | Human antibodies that bind human 17-A1/EpCAM tumor antigen |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6194551B1 (en) * | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| PT2180007E (pt) | 1998-04-20 | 2013-11-25 | Roche Glycart Ag | Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US6311415B1 (en) | 1998-09-14 | 2001-11-06 | Lind Shoe Company | Bowling shoe with replaceable tip |
| CA2359067C (en) | 1999-01-15 | 2017-03-14 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP2270147B2 (en) | 1999-04-09 | 2020-07-22 | Kyowa Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| WO2001029246A1 (fr) | 1999-10-19 | 2001-04-26 | Kyowa Hakko Kogyo Co., Ltd. | Procede de production d'un polypeptide |
| WO2001029224A2 (en) | 1999-10-20 | 2001-04-26 | Zymogenetics, Inc. | Granulocyte peptide homolog zgpa1 |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| WO2002030954A1 (fr) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kogyo Co., Ltd. | Procede de purification d'un anticorps |
| AP2003002800A0 (en) | 2000-10-13 | 2003-06-30 | Richard Boyd | Hematopoietic stem cell gene therapy |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| EP1351707B9 (en) | 2001-01-09 | 2012-01-25 | Baylor Research Institute | Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays |
| WO2003016472A2 (en) | 2001-08-12 | 2003-02-27 | Pepgen Corporation | Hybrid interferon/interferon tau proteins, compositions and methods of use |
| US7151164B2 (en) * | 2002-02-14 | 2006-12-19 | Immunomedics, Inc. | Anti-CD20 antibodies and fusion proteins thereof and methods of use |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| EP2364996B1 (en) * | 2002-09-27 | 2016-11-09 | Xencor Inc. | Optimized FC variants and methods for their generation |
| US20060134105A1 (en) * | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
| KR101223373B1 (ko) | 2003-12-25 | 2013-01-16 | 교와 핫꼬 기린 가부시키가이샤 | 항 ｃｄ４０ 항체의 변이체 |
| DK1737891T3 (da) * | 2004-04-13 | 2013-03-25 | Hoffmann La Roche | Anti-p-selectin-antistoffer |
| SI1781705T1 (sl) | 2004-06-21 | 2015-01-30 | Medarex, L.L.C. | Interferon alfa receptor i protitelesa in njihova uporaba |
| EP1781704A2 (en) * | 2004-07-30 | 2007-05-09 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
| WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| DK2325207T3 (en) | 2004-11-12 | 2017-06-06 | Xencor Inc | Fc variants with altered binding to FcRn |
| EP1858925A2 (en) | 2005-01-12 | 2007-11-28 | Xencor, Inc. | Antibodies and fc fusion proteins with altered immunogenicity |
| WO2006099451A2 (en) | 2005-03-14 | 2006-09-21 | University Of Medicine & Dentistry Of New Jersey | Novel human, feline, chicken and other animal interferons and uses thereof |
| SI2219452T1 (sl) | 2007-11-05 | 2016-03-31 | Medimmune, Llc | Postopki zdravljenja skleroderme |
| KR101666229B1 (ko) * | 2008-02-08 | 2016-10-14 | 메디뮨 엘엘씨 | Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체 |
| US11392902B2 (en) | 2017-06-06 | 2022-07-19 | United Parcel Service Of America, Inc. | Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery |
-
2009
- 2009-02-06 KR KR1020107019995A patent/KR101666229B1/ko active IP Right Grant
- 2009-02-06 BR BR122020023189-0A patent/BR122020023189B1/pt active IP Right Grant
- 2009-02-06 CN CN200980104557.7A patent/CN101952454B/zh active Active
- 2009-02-06 PT PT09707396T patent/PT2250279E/pt unknown
- 2009-02-06 WO PCT/US2009/033358 patent/WO2009100309A2/en active Application Filing
- 2009-02-06 JP JP2010546038A patent/JP5608100B2/ja active Active
- 2009-02-06 EP EP09707396.9A patent/EP2250279B1/en active Active
- 2009-02-06 HU HUE09707396A patent/HUE028958T2/en unknown
- 2009-02-06 PL PL09707396.9T patent/PL2250279T3/pl unknown
- 2009-02-06 DK DK09707396.9T patent/DK2250279T3/en active
- 2009-02-06 SG SG2013009865A patent/SG188129A1/en unknown
- 2009-02-06 SI SI200931472A patent/SI2250279T1/sl unknown
- 2009-02-06 ES ES09707396.9T patent/ES2581917T3/es active Active
- 2009-02-06 US US12/866,579 patent/US20110059078A1/en not_active Abandoned
- 2009-02-06 BR BRPI0907735-9A patent/BRPI0907735B1/pt active IP Right Grant
- 2009-02-06 KR KR1020167014946A patent/KR20160070165A/ko not_active Application Discontinuation
- 2009-02-06 MX MX2010008578A patent/MX2010008578A/es active IP Right Grant
- 2009-02-06 AU AU2009212273A patent/AU2009212273B2/en active Active
- 2009-02-06 CA CA2713981A patent/CA2713981C/en active Active
-
2011
- 2011-04-07 HK HK11103558.5A patent/HK1149297A1/zh unknown
-
2016
- 2016-07-12 CY CY20161100661T patent/CY1117827T1/el unknown
- 2016-07-12 HR HRP20160855TT patent/HRP20160855T1/hr unknown
-
2017
- 2017-09-21 US US15/711,197 patent/US9988459B2/en active Active
-
2018
- 2018-05-04 US US15/971,127 patent/US10301390B2/en active Active
-
2019
- 2019-04-08 US US16/377,769 patent/US20200172625A1/en not_active Abandoned
- 2019-07-15 US US16/511,600 patent/US20200055944A1/en not_active Abandoned
-
2022
- 2022-05-16 HU HUS2200023C patent/HUS2200023I1/hu unknown
- 2022-05-16 HU HUS2200022C patent/HUS2200022I1/hu unknown
- 2022-05-17 NL NL301175C patent/NL301175I2/nl unknown
- 2022-05-18 FR FR22C1019C patent/FR22C1019I2/fr active Active
- 2022-05-25 NO NO2022016C patent/NO2022016I1/no unknown
- 2022-06-27 LT LTPA2022514C patent/LTPA2022514I1/lt unknown
- 2022-06-30 FI FIC20220024C patent/FIC20220024I1/fi unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011514150A5 (ja) | ||
| JP2018183173A5 (ja) | ||
| JP2016512551A5 (ja) | ||
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| JP6962915B2 (ja) | 改善されたｔｎｆ結合因子 | |
| JP2018527919A5 (ja) | ||
| JP2014526898A5 (ja) | ||
| JP2018521691A5 (ja) | ||
| JP2019501883A5 (ja) | ||
| JP2014158469A5 (ja) | ||
| JP2018532766A5 (ja) | ||
| JP2014511179A5 (ja) | ||
| JP2018500014A5 (ja) | ||
| RU2017119185A (ru) | Антитела против fgfr2/3 и способы их применения | |
| JP2015533795A5 (ja) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| JP2015520758A5 (ja) | ||
| JP2016507555A5 (ja) | ||
| JP2018537421A5 (ja) | ||
| JP2012530496A5 (ja) | ||
| JP2013538057A5 (ja) | ||
| JP2009519718A5 (ja) | ||
| JP2012524071A5 (ja) | ||
| JP2009533020A5 (ja) | ||
| JP2015525795A5 (ja) |